Myriad Genetics, Inc. (MYGN) stock analysis
Healthcare · Diagnostics & Research
From the 10-K filed 2026-02-24
How it makes money
Healthcare providers and patients pay for genetic tests to guide medical treatment decisions.
Healthcare providers and patients pay for molecular tests to uncover genetic insights. These tests assist in assessing disease risk or progression to guide treatment decisions across medical specialties.
What protects it: the moat
Management claims its reputation for quality and extensive commercial reach protect its market position.
The company relies on its established presence in community medicine to integrate its solutions into clinical workflows. It also cites its reputation for high-quality tests as a key differentiator.
What growth costs
It must reinvest in science, innovation, and next-generation laboratory facilities to scale.
To grow, the company invests in clinical evidence development and technology-enabled operations. It also recently transitioned to new laboratory facilities designed to improve automation and cost efficiency.
What could damage it
Revenue is threatened if government or third-party payors stop covering or paying for tests.
The business model relies on reimbursement from insurance and government programs. If these entities reduce coverage or payment levels, it directly harms the company's revenue and profitability.
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.